2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
February 19th 2022
The combination of lenvatinib and pembrolizumab produced similar efficacy and safety profiles in an East Asian subgroup of patients with advanced renal cell carcinoma.
December 14th 2021
Data from a longer follow-up analysis of the phase 1/2 CARTITUDE-1 trial demonstrated that all evaluated subgroups of patients with relapsed/refractory multiple myeloma maintained durable responses with ciltacabtagene autoleucel.
September 8th 2021
Because standardized treatment approaches have not been established for patients with low-risk myelodysplastic syndromes and limited options are available to those with erythropoietin failure, the need for varied clinical trials is underscored.
June 12th 2021
In the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large b-cell lymphoma in the outpatient setting who are receiving the CAR T-cell therapies prior to failure on 2 prior lines of therapy.
June 10th 2021
The combination of regorafenib plus pembrolizumab in the first-line setting for patients with advanced hepatocellular carcinoma showed encouraging anti-tumor activity with a disease control rate of 91%, and did not display any new safety signals.
June 4th 2021
Evidence of tucatinib and its predominant metabolite, ONT-993, were detectable in the cerebrospinal fluid of patients with leptomeningeal metastasis HER2+ positive breast cancer marking a first for tucatinib distribution into the CSF seen in this patient population.
February 10th 2021
February 10, 2021 - The JAK 1/2 inhibitor ruxolitinib, when given at a maximum dose of 10 mg peri-transplant, has been shown to be safe and feasible in patients with myelofibrosis.
December 11th 2020
December 11, 2020 - Gastrointestinal adverse events that occurred in patients with metastatic breast cancer who were treated with oral paclitaxel and encequidar can be managed by the use of 5- HT3 inhibitors and early intervention with loperamide.
May 13th 2020
People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.